HIV/AIDS Therapy
Enfuvirtide is first fusion inhibitor for treating patients with HIV
Published in AIDS Vaccine Week, June 30th, 2003
According to recent research from the United States, "Enfuvirtide (Fuzeon, Roche/Trimeris) is the first member of a unique class of antiretrovirals known as the fusion inhibitors to gain Food and Drug Administration approval for the treatment of human immunodeficiency virus type-1 (HIV-1) infection. Enfuvirtide is indicated for use in combination with other antiretroviral agents in the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy."
"Preliminary trials...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
Source: AIDS Vaccine Week (2003-06-30)
More Articles from AIDS Vaccine Week
- At-Risk Populations
Study will evaluate recombinant canarypox HIV-1 vaccine in IV drug users - Etiology
Research sheds further light on the origins of HIV-1 - AIDS Vaccine
Company presents preclinical results from AIDS vaccine program - HIV/AIDS Vaccine
Systemic priming with mucosal boosting shows promise in animals - Therapeutic Vaccines
Patent granted for herpes vaccine; peptide may be used as adjuvant for vaccines - AIDS Drug Prices
Drug giant urged to resolve pricing battle - More from this issue of AIDS Vaccine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
